共 12 条
- [2] 骨髓增殖性疾病中JAK2V617F基因突变及与临床特征的关系[J]. 朱俊芳,刘媛,刘蓓,贾明峰,成娟,赵丽.中国实验血液学杂志. 2011(04)
- [6] Incidence Rates and Risk Factors for Vascular Events in Patients With Essential Thrombocythemia: A Multicenter Study From Korea[J] . Ho Sup Lee,Lee Chun Park,Eun Mi Lee,Shin Jun Lee,Seong Hoon Shin,Hana Im,Kil Min Do,Eeon Jin Kim,Byeong Jin Ye,Moo Kon Song,Sung-Hyun Kim,Sang Min Lee,Won Sik Lee,Yang Soo Kim.Clinical Lymphoma Myeloma and Leukemia . 2012 (1)
- [7] Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management[J] . AyalewTefferi.Am. J. Hematol. . 2012 (3)
- [9] JAK2V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients[J] . Francesca Palandri,Emanuela Ottaviani,Federica Salmi,Lucia Catani,Nicola Polverelli,Mauro Fiacchini,Giovanni Martinelli,Michele Baccarani,Nicola Vianelli.Leukemia & Lymphoma . 2009 (2)
- [10] V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules[J] . Anna Falanga,Marina Marchetti,Alfonso Vignoli,Donatella Balducci,Laura Russo,Vittoria Guerini,Tiziano Barbui.Experimental Hematology . 2007 (5)